The standard of care—intravitreal anti-VEGF injections—requires a lifelong, high-frequency regimen. This demanding schedule creates significant treatment burden, often leading to poor compliance and under-treatment. Fluctuating therapeutic levels between injections can cause disease reactivation, highlighting a critical unmet need for continuous disease suppression.
Pipeline
NG101
Unburdening Vision:
A New Therapeutic Future
NG101
| Indication | Developmental stage | Transgene | Injection route | Serotype |
|---|---|---|---|---|
| Wet AMD | Clinical Development (Phase 1/2a) | Aflibercept | Subretinal Injection | AAV8 |
About wet AMD
Wet Age-related Macular Degeneration is a primary cause of irreversible blindness, driven by the pathological overexpression of VEGF. This triggers choroidal neovascularization, causing fluid accumulation and structural damage that leads to progressive central vision loss.
The Challenge of Current Therapies
Our Approach: NG101
NG101 is an investigational gene therapy designed to establish a new treatment paradigm for wet AMD. Following a single subretinal injection, NG101 leverages a clinically validated AAV vector to enable continuous, endogenous expression of a potent anti-VEGF protein directly from the retina itself.
By maintaining stable therapeutic protein levels from a single administration, NG101 is engineered to deliver durable disease control while substantially reducing the burden of chronic intravitreal injections. Optimized for high efficacy at a low vector dose — a design choice intended to minimize dose-related inflammation and other adverse events — NG101 aims to offer lasting vision protection and fundamentally transform the management of wet AMD.
